Article Text

PDF
SAT0689 Prevalence of and temporal trends in hyperuricaemia among adult patients with chronic kidney disease in ireland
  1. F Adeeb1 2,
  2. AA Udayakumar2 3,
  3. D Ryan2,
  4. X Li2,
  5. AD Fraser1 2,
  6. AG Stack2 3,
  7. on behalf of Health Research Institute, University of Limerick
  1. 1Department of Rheumatology, University Hospital Limerick
  2. 2Graduate Entry Medical School, University of Limerick
  3. 3Department of Nephrology, University Hospital Limerick, Limerick, Ireland

Abstract

Background An increasing body of evidence links hyperuricaemia with the development of several metabolic disorders and major cardiovascular outcomes. A better understanding of the burden and variation of hyperuricemia within the health system is important in order to identify high-risk groups and facilitate early intervention with effective management strategies.

Objectives The aim of this study was to describe the prevalence of hyperuricaemia, and period trends within the Irish Health System among patients with chronic kidney disease (CKD).

Methods 136,325 adult CKD patients aged 18 and above with valid measurements of serum uric acid and creatinine levels were identified between 2006 and 2014 from the laboratory systems within the Irish health system. Hyperuricaemia was defined as serum uric acid ≥420μmol/L in men and ≥360μmol/L in women. Estimated glomerular filtration rates were determined using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation and patients were classified by CKD stage according to the Kidney Disease Improving Global Outcomes (KDIGO) staging system. Age- and sex-specific prevalence of hyperuricemia estimates with 95% confidence intervals were determined for each group and across calendar years. Comparisons among groups and across years were conducted using chi-square and multivariate logistic regression was used to explore associations using adjusted odds ratios (AOR) and 95% Confidence Intervals (CI).

Results Patients with hyperuricaemia were noted to be older [58.2 (18.5) vs. 51.2 (17.4) years]. The prevalence of hyperuricaemia increased progressively between 2006 and 2014 from 20.3% (19.5, 21.0) to 26.5% (25.8, 27.2%) in men and from 17.9% (17.2, 18.6) to 20.4% (19.8, 21.0) in women, p<0.001. Age-specific prevalence increased significantly over time for all age groups (18–39, 40–59, 60–79, and ≥80 years) for men and women, p<0.001. Prevalence was significantly higher with more advanced CKD stage: 15.1% (14.5, 15.6) in Stage 1 CKD compared to 43.0% (34.8, 51.1) in Stage 5 CKD, p<0.001. However, rates fell significantly for those Stage 4 and 5 CKD respectively (Figure1). In multi-variable models, the adjusted likelihood of hyperuricaemia increased with each successive year (Figure 2).

Conclusions The prevalence of hyperuricaemia is substantial in the Irish health system and has increased in frequency over the past decade. Although the burden was highest among patients with more advanced CKD, an encouraging decline in prevalence was observed in recent years. Greater management of gout and hyperuricaemia from increasing utilization of urate-lowering therapies may be responsible for this trend.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.